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Abstract
Background: As we have previously reported, small cell carcinoma of the ovary (SCCO) is a rare, aggressive form of
ovarian cancer associated with poor outcomes. In an effort to identify new treatment options, we utilized
comprehensive genomic profiling to assess the potential for novel therapies in SCCO.
Methods: Patients with SCCO, SCCO-HT (hypercalcemic type), neuroendocrine tumors of the ovary (NET-O), and
small cell carcinoma of the lung (SCLC) profiled by Caris Life Sciences between 2007–2015 were identified. Tumors
were assessed with up to 21 IHC stains, in situ hybridization of cMET, EGFR, HER2 and PIK3CA, and next-generation
sequencing (NGS) as well as Sanger sequencing of selected genes.
Results: Forty-six patients with SCCO (10 SCCO, 18 SCCO-HT, 18 NET-O) were identified as well as 58 patients with
SCLC for comparison. Patients with SCCO and SCCO-HT were younger (median 42 years [range 12–75] and 26 years
[range 8–40], respectively) than patients with NET-O 62 [range 13–76] or SCLC 66 [range 36–86]. SCCO patients
were more likely to be metastatic (70 %) than SCCO-HT (50 %) or NET-O (33 %) patients, but at a similar rate to
SCLC patients (65 %). PD1 expression varied across tumor type with SCCO (100 %), SCCO-HT (60 %), NET-O (33 %)
vs SCLC (42 %). PDL1 expression also varied with SCCO (50 %), SCCO-HT (20 %), NET-O (33 %) and SCLC (0 %). No
amplifications were identified in cMET, EGFR, or HER2 and only 1 was found in PIK3CA (NET-O). Actionable
mutations were rare with 1 patient with SCCO having a BRCA2 mutation and 1 patient with NET-O having a PIK3CA
mutation. No other actionable mutations were identified.
Conclusions: No recurrent actionable mutations or rearrangements were identified using this platform in SCCO.
IHC patterns may help guide the use of chemotherapy in these rare tumors.
Keywords: Gynecologic malignancies, Small cell carcinoma of ovary, Genomic profiling, Actionable mutation,
Chemotherapy
Abbreviations: CISH, Chromogenic in situ hybridization; FISH, Fluorescence in situ hybridization;
IHC, Immunohistochemistry; NET-O, Neuroendocrine tumor of the ovary; NGS, Next generation sequencing;
NSCLC, Non-small cell lung carcinoma; SCCO, Small cell carcinoma of the ovary; SCCO-HT, Small cell carcinoma of
the ovary–hypercalcemic type; SCLC, Small cell lung carcinoma
* Correspondence: pprouet@uthsc.edu
3Department of Internal Medicine, The University of Tennessee Health
Science Center, 956 Court Ave., Suite H314, Memphis, TN 38163, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yaghmour et al. Journal of Ovarian Research  (2016) 9:52 
DOI 10.1186/s13048-016-0259-2
Background
Small cell carcinoma of the ovary (SCCO) is a very rare
and aggressive form of ovarian cancer that carries a poor
prognosis despite early median age at diagnosis. SCCO
presents challenges for diagnosis, prediction of outcomes,
and overall treatment strategies [1, 2]. Due to limited data,
there are no defined treatment protocols [3].
Molecular mechanisms underlying development and
progression of SCCO remain poorly understood. Inactiva-
tion in SMARCA4, which codes for BRG1, in small cell
carcinoma of the ovary hypercalcemic type (SCCO-HT)
has been described in 75-100 % of cases. SMARCA4 is a
member of the SWI/SNF chromatin-remodeling gene
complex, which has been shown to be mutated in several
different cancers. SMARCA4 inactivation appears to be a
specific diagnostic marker in SCCOHT [4–7]. This inacti-
vation, however, does not define any treatment strategies
that would be defined with actionable abnormalities.
Profiling of rare tumors using the Caris Molecular
Intelligence platform has yielded potential targets in vari-
ous tumor types. Burzawa, et al. analyzed on 78 samples
of small cell cancer of the cervix using Caris Molecular
Intelligence (53 samples) and a 50-gene next-generation
sequencing (NGS) platform (25 samples). They showed
elevated expression of TOPO2A and TOPO1 implying
sensitivity to etoposide and topotecan, respectively. They
also described potentially targetable mutations in Akt1,
KRAS, PIK3CA, and TP53. One of the patients who had a
KRAS mutation showed a complete response to MEK
inhibitor therapy ongoing for more than 12 months [8].
PIK3CA mutations were identified as potential targets in
small call carcinoma of the breast in another study using
the Caris Molecular Intelligence platform [9].
Caris Molecular Intelligence is a multi-platform tumor
profiling service that includes gene sequencing (next-gen-
eration sequencing [NGS] and Sanger), protein expression
analysis (immunohistochemistry [IHC]), and gene copy
number and translocation analysis (chromogenic or fluor-
escence in situ hybridization [CISH or FISH]). As patients
living with these malignancies have few therapeutic op-
tions, we hypothesized that Caris Molecular Intelligence
may provide clinically relevant information for women
with SCCO [10].
Methods
After obtaining Institutional Review Board approval from
the University of Tennessee we queried the Caris Life
Sciences database for patients profiled by Caris Molecular
Intelligence using the keywords “small cell” to search in
the clinical history and diagnosis fields for cases of SCCO,
SCCO-HT (hypercalcemic type), neuroendocrine tumors
of the ovary (NET-O) from 2007–2015. Comparative data
was pulled for SCLC from April 2015- September 2015.
Caris registry is a proprietary database to which the
investigators have access for research purposes, which
collates and categorizes molecular alterations and cancer
types across patients who have had cancer molecular te-
sting done throughout The United States using a multi-
platform tumor profiling service that includes gene
sequencing with NGS and Sanger, protein expression
analysis with IHC, and gene copy number and transloca-
tion analysis with CISH or FISH.
Clinicopathologic characteristics of patients with SCCO,
SCCO-HT, NET-O and SCLC patients were identified,
including age and whether metastatic disease was present
at the time of profiling. IHC analysis was performed using
commercially available detection kits and automated
staining techniques (Benchmark XT, Ventana, Tucson,
AZ; and AutostainerLink 48, Dako, Carpinteria, CA). Tu-
mors were assessed with up to 25 IHC stains (ALK, AR,
BCRP, c-KIT, ER, PR, cMET, EGFR, HER2, IGF1R, PTEN,
PD-1, PDGFR, PD-L1, ERCC1, TS, MGMT, RRM1, TLE3,
TUBB3, SPARC, TOP2A, TOPO1, MRP1, PGP). Gene
copy number alterations of cMET, EGFR, HER2, PIK3CA,
and TOP2A were analyzed by DNA ISH using (FISH and/
or CISH probes as part of automated staining techniques
(Benchmark XT, Ventana, Tucson, AZ) and automated
imaging systems (BioView, Billerica, MA). The ratio of
gene to pericentromeric regions of chromosome 7 (EGFR,
cMET), 17 (HER2, TOP2A) and 3 (PIK3CA) were used to
determine increases in gene copy number. Tumors also
underwent NGS analysis, which is a form of parallel
sequencing that greatly enhances the efficiency of identify-
ing both somatic and germline mutations [11]. NGS se-
quencing was performed on genomic DNA isolated from
tumor tissue using the Illumina MiSeq platform. PCR
products were bi-directionally sequenced using the Big-
Dye Terminator v1.1 chemistry, analyzed using the 3730
DNA Analyzer (Applied Biosystems, Grand Island, NY).
Sequence traces were analyzed using Mutation Surveyor
software v3.25 (Soft Genetics, State College, PA). NGS
and Sanger sequencing of a 47-gene panel (ABL, AKT,
ALK, APC, ATM, BRAF, BRCA1, BRCA2, CDH1, cKIT,
cMET, CSF1R, CTNNB1, EGFR, ERBB4, FBXW7, FGFR1,
FGFR2, FLT3, GNA11, GNAQ, GNAS, HER2, HNF1A,
HRAS, IDH1, JAK2, JAK3, KDR, KRAS, MLH1, MPL,
NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN,
PTPN11, RB, RET, SMAD4, SMARCB1, SMO, STK11,
TP53, VHL) was evaluated for somatic mutations.
Coding changes were accessed for pathogenicity using
PolyPhen-2 [10, 12].
Retrospective analysis of biomarker frequency distribu-
tions was attained using standard descriptive statistics
evaluating the incidence of the aforementioned genomic
alterations in these tumors by Caris Molecular Intelligence
profiling. The two-tail Fisher’s exact test analyzed
whether frequencies differed by subgroup, specifically
to determine if any non-random associations between
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SCCO and SCLC existed. A p-value <0.05 was considered
statistically significant and all p-values were 2-sided.
Results
Forty-six unique patients with SCCO were identified that
had profiling between 2007–2015. These included 10 pa-
tients with SCCO with median age of 42 (range 12–75),
18 patients with “small cell/hypercalcemic” (SCCO-HT)
with median age of 26 (range 8–40), and 18 patients with
“neuroendocrine” (NET-O) with median age of 62 (range
13–76). 70 % of SCCO patients, 50 % of SCCO-HT pa-
tients, and 33 % NET-O patients had metastatic disease at
presentation. For comparison, 58 patients with SCLC were
identified. The median age was 66 (range 36–86), and
65 % had metastatic disease at presentation (Table 1).
By IHC, 100 % of SCCO patients (2/2), 60 % of SCCO-
HT patients (3/5), and 33 % of NET-O (1/3) subtypes
expressed PD1, while 42 % of SCLC patients (22/53)
expressed PD1. Moreover, 50 % of SCCO patients (1/2),
20 % of SCCO-HT patients (1/5), and 33 % of NET-O
patients (1/3) expressed PDL1, while 0 patients with
SCLC (0/54) expressed PDL1. (SCCO 1/2 vs. SCLC 0/
54 [p-value = 0.036]). In addition, by IHC, 100 % of
SCCO patients (7/7), 92 % of SCCO-HT patients (11/12),
and 69 % of NET-O patients (11/16) expressed TOP2A,
while 95 % of patients with SCLC (52/55) expressed
TOP2A. (NET-O 11/16 vs. SCLC 52/55 [p-value = 0.012]).
Also 8 % (1/12) of SCCO-HT patients, 33 % (4/12) of
NET-O, and 50 % (1/2) SCCO patients expressed ERCC1.
Moreover, 10 % (1/10) of SCCO patients, 38 % (6/16) of
SCCO-HT patients, and 59 % (10/17) of NET-O patients
expressed MGMT, while 13 % of SCLC patients (7/
55) expressed MGMT. (NET-O 10/17 vs. SCLC 7/55
[p-value =0.0003]). Also, 88 % (7/8) of SCCO patients
expressed RRM1. SCCO and SCLC patients had simi-
lar patterns of other IHC expression (Fig. 1).
No amplifications were identified in cMET, EGFR, or
HER2 by ISH in any neuroendocrine cancer of the ovary.
PIK3CA was amplified by ISH in NET-O patients in 33 %
(1/3) of patients (Table 2). NGS and Sanger sequencing of a
47-gene panel revealed TP53 mutations in 25 % of SCCO
(1/4) patients and BRCA2 mutations in 50 % of SCCO
(1/2) patients. PIK3CA mutations were seen in 16 % (1/6)
of sequenced NET-O patients, but no SCLC patients. No
other actionable mutations were identified (Fig. 2).
Discussion
In contrast to other tumor types, Caris Molecular
Intelligence did not identify recurrent actionable mu-
tations or alterations in the subtypes of SCCO. IHC
patterns suggested potential sensitivities to chemotherapy.
Alternative methods of genomic interrogation, such as
total exon sequencing, may discover actionable targets.
Neuroendocrine cancers of the ovary were similar when
profiled by Caris Molecular Intelligence to SCLC.
Table 1 Median age and % Metastatic disease at presentation
of SCCO, SCCO-HT, NET-O, and SCLC
Small Cell Cancer Type Median Age %Metastatic
SCCO (n = 10) 42 (12–75) 70 %
SCCO-HT (n = 18) 26 (8–40) 50 %
NET-O (n = 18) 62 (13–76) 33 %
SCLC (n = 58) 66 (36–86) 65 %
Fig. 1 Biomarker Differences btw Rare Ovarian Cancers by IHC
Yaghmour et al. Journal of Ovarian Research  (2016) 9:52 Page 3 of 5
IHC testing for biomarker differences between these
rare tumor subtypes showed high rates of TOP2A (100
% of SCCO patients, 92 % of SCCO-HT patients and 69
% of NET-O patients) in all 3 subtypes of neuroendo-
crine cancers of the ovary, implicating the use of topo-
isomerase inhibitors as rationale treatment options.
Topoisomerase inhibitors such as pegylated liposomal
doxorubicin have been commonly used as second line
therapy in platinum resistant ovarian cancer [13]. Thi-
bault et al. showed that inhibition of topoisomerase II
using polyamine vectorized inhibitor (F14512) signifi-
cantly inhibited tumor growth in ovarian cells and con-
stitutes a potential new therapy for platinum resistant
ovarian cancer [14].
Platinum-based therapies are the current standard of
care for ovarian cancer. However, drug resistance plays an
important role in determining overall survival. Expression
of ERCC1, a strategic marker of nucleotide excision repair,
has been associated with resistance to platinum based
chemotherapy [15]. SCCO-HT exhibited the lowest rate
of ERCC1 in our study, implicating the use of platinum
based regimens for this sub-type.
MGMT, a DNA repair enzyme, plays a crucial role
in mediating resistance to alkylating agents in various
tumors, especially malignant gliomas. Epigenetic silen-
cing of this gene has resulted in increased chemo-
sensitivity by compromising DNA repair mechanisms.
Temozolomide, an alkylating agent, is currently being
tested as a single agent for ovarian cancer but has
the potential for second line therapy in combination
with methoxyamine for patients that have failed plat-
inum and paclitaxel chemotherapy [16, 17]. Our data
showed that SCCO exhibited the lowest rate of
MGMT, implicating alkylating agents such as temozo-
lomide as a potential agent to be used.
Elevated levels of RRM1 gene have been associated
with poor outcomes in advanced NSCLC treated with
gemcitabine [18, 19]. Several studies have been con-
ducted to explore the potential benefit of gemcitabine in
ovarian cancer. Ferrandina et al. looked at both RRM1
and RRM2 in primary ovarian cancer and observed
shorter OS with higher RRM2 expression [20]. Our cases
of SCCO had high expression of RRM1 but NET-O
exhibited the lowest rate of RRM1 expression, implicat-
ing gemcitabine as a useful agent for NET-O.
Blocking the PD1/PDL1 interaction is being studied
in several malignancies with good responses. Our sub-
set of SCCO had a high expression of PD1 and PDL1
and the therapeutic potential of this pathway needs to
be explored.
Mutations detected by hot spot sequencing panel
were infrequent events and amplification by ISH were
rare as well. Rare ovarian cancers would benefit from
expanded mutation profiling to identify additional po-
tential targets as well as confirm the presence of
SMARCA4 in SCCO-HT.
Our study had some limitations. This was a retrospect-
ive analysis of a limited number of cases. Due to the
rarity of this disease only 46 cases were identified and
statistical analysis could not be performed. The lack of
information such as patient demographics, treatment
modalities and outcome prevented us from determining
clinical correlation.
Table 2 Amplifications detected by in situ hybrization
cMET EGFR HER2 PIK3CA
SCCO 0/4 0/2 0/9 n/a
SCCO-HT 0/9 0/2 0/13 n/a
NET-O 0/10 0/1 0/15 1/3
Fig. 2 Sequencing results by NGS/Sanger
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Conclusion
Neuroendocrine cancers of the ovary are rare malignan-
cies. With no recurrent actionable mutations, treatment
remains a challenge. Future clinical trials looking at stand-
ard of care chemotherapy using platinum based chemo-
therapeutics and comparing that to specific chemotherapy
regimens based off of IHC mutations may prove to be of
significance in treating this rare disease. Our study showed
that all SCCO types showed high expression of TOP2A,
therefore, trials comparing platinum based therapies to
topoisomerase II inhibitors such as doxorubicin or etopo-
side in patients who have high expression of ERCC1,
which is associated with platinum resistance, may lead to
a change in our approach to this subset of diseases. Also,
there is potential for clinical trials comparing standard
chemotherapy to PD1/PDL1 inhibition in SCCO as our
subset of SCCO patients showed increased expression
of PD1 and PDL1. Novel treatment options can be used
on a case-by-case basis depending on the genomic pro-
file. Prospective studies need to be conducted for better
results, but given the rarity of this disease, that may
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